March 19 (Reuters) - Resverlogix Corp:
* RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
* RESVERLOGIX CORP - EXPLORING OPTION OF US ENROLLMENT IN BETONMACE TRIAL AS WELL AS OPTION OF RELYING ON EXISTING BETONMACE DATA TO FILE A US NDA
* RESVERLOGIX CORP - PRIMARY ENDPOINT READ-OUT OF ONGOING PHASE 3 BETONMACE TRIAL AROUND END OF 2018 Source text for Eikon: Further company coverage: